Hicks S B, Tabibian J H
Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
J Mol Genet Med. 2017;11(4). doi: 10.4172/1747-0862.1000301. Epub 2017 Nov 27.
Despite the many advancements in liver transplantation (LT), mortality in patients with hepatic failure remains high, and to date, many patients die while awaiting LT. The molecular adsorbent recirculating system (MARS) is an extracorporeal liver support system intended to provide short-term metabolic detoxification, often as a vital bridge to LT. We report the case of a 41-year-old non-Hispanic White male who developed worsening multi-factorial encephalopathy in the setting of decompensated alcoholic cirrhosis. He continued to deteriorate despite supportive medical therapy, and extensive investigation for alternative causes of encephalopathy aside from hepatic was unrevealing; as a result, there was concern that his encephalopathy was due to irreversible causes from which he may not recover appropriately following LT. We herein: i) describe the implementation of MARS as a diagnostic intervention for encephalopathy of uncertain etiology in a patient with end stage liver disease who, on the basis of prompt psychomotor improvement, underwent LT 19 days post-MARS implementation with an excellent clinical outcome and thus ii) propose the use of extracorporeal liver support not only as a short-term bridge but also as a diagnostic (and potentially therapeutic) measure in cases of cryptogenic encephalopathy, particularly in the setting of advanced liver disease.
尽管肝移植(LT)取得了诸多进展,但肝功能衰竭患者的死亡率仍然很高,迄今为止,许多患者在等待肝移植期间死亡。分子吸附再循环系统(MARS)是一种体外肝脏支持系统,旨在提供短期代谢解毒,通常作为肝移植的重要桥梁。我们报告了一例41岁非西班牙裔白人男性病例,该患者在失代偿性酒精性肝硬化背景下出现多因素性脑病恶化。尽管接受了支持性药物治疗,他的病情仍持续恶化,除肝脏因素外,对脑病的其他病因进行了广泛调查,但未发现异常;因此,有人担心他的脑病是由不可逆病因引起的,肝移植后可能无法适当恢复。我们在此:i)描述了MARS作为对一名终末期肝病患者病因不明的脑病的诊断性干预措施的实施情况,该患者在MARS实施后19天接受了肝移植,基于快速的精神运动改善,临床结局良好;因此ii)建议在隐源性脑病病例中,尤其是在晚期肝病的情况下,将体外肝脏支持不仅作为短期桥梁,而且作为一种诊断(可能也是治疗)措施。